FOLR1 and neoplasm: In nearly 90% of the non-mucinous ovarian cancer, FRα expression has been observed and correlated with tumor grade, stage, aggressiveness and its expression is maintained after chemotherapy in epithelial ovarian and endometrial cancer6,7.